Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion description "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion evidence source_evidence_literature NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion SIO_000772 12506022 NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion wasDerivedFrom befree-20140225 NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion wasGeneratedBy ECO_0000203 NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- befree-20140225 importedOn "2014-02-25" NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.